Some methodologies, employed in both human and veterinary cancer treatments, encompass the utilisation of autologous tumour cells and/or their extracts, sometimes combined with bacterial adjuvants as well as genetically altered tumour cells [18,19,20,21], heat-shock proteins (HSP) [22,23], and tumour-specific peptides [24]. This evidence concerns the gene HSP90B2P and neoplasm.